Senores Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


0.77×	0.76×	0.83×
1.02×	1.16×	0.97×
24.3%	21.7%	18.3%
0.45×	0.45×	0.32×
1.63×	1.66×	1.51×
13.9%	14.4%	7.1%
14.1%	14.1%	7.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SENORES₹1,219.20

Senores Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSANOFI INNOVACAP MOREPENLAB IOLCP FDC PGHL SANOFICONR ORCHPHARMAMcap ₹5,614 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.83	0.76	0.77
Interest Burden (Pretax/EBIT) ×	0.97	1.16	1.02
EBIT Margin %	18.30	21.67	24.31
Asset Turnover ×	0.32	0.45	0.45
Financial Leverage (Assets/Equity) ×	1.51	1.66	1.63
ROE (5-step product, year-end total equity) %	7.08	14.37	13.94
ROE (owners' profit / average owners' equity) %	7.42	14.13	14.13

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.